- Home
- STAA vs ARQT Comparison
STAA vs ARQT Comparison
Compare STAA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAA
- ARQT
- Stock Information
- Founded
- STAA 1982
- ARQT 2016
- Country
- STAA United States
- ARQT United States
- Employees
- STAA N/A
- ARQT N/A
- Industry
- STAA Ophthalmic Goods
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- STAA Health Care
- ARQT Health Care
- Exchange
- STAA Nasdaq
- ARQT Nasdaq
- Market Cap
- STAA 850.9M
- ARQT 1.7B
- IPO Year
- STAA N/A
- ARQT 2020
- Fundamental
- Price
- STAA $17.17
- ARQT $15.00
- Analyst Decision
- STAA Hold
- ARQT Strong Buy
- Analyst Count
- STAA 8
- ARQT 6
- Target Price
- STAA $27.17
- ARQT $18.80
- AVG Volume (30 Days)
- STAA 746.9K
- ARQT 2.0M
- Earning Date
- STAA 08-06-2025
- ARQT 08-13-2025
- Dividend Yield
- STAA N/A
- ARQT N/A
- EPS Growth
- STAA N/A
- ARQT N/A
- EPS
- STAA N/A
- ARQT N/A
- Revenue
- STAA $279,134,000.00
- ARQT $212,819,000.00
- Revenue This Year
- STAA N/A
- ARQT $61.15
- Revenue Next Year
- STAA $29.34
- ARQT $37.98
- P/E Ratio
- STAA N/A
- ARQT N/A
- Revenue Growth
- STAA N/A
- ARQT 100.03
- 52 Week Low
- STAA $13.50
- ARQT $7.86
- 52 Week High
- STAA $49.86
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- STAA 49.02
- ARQT 60.23
- Support Level
- STAA $16.52
- ARQT $13.06
- Resistance Level
- STAA $18.00
- ARQT $15.36
- Average True Range (ATR)
- STAA 0.69
- ARQT 0.66
- MACD
- STAA 0.09
- ARQT 0.12
- Stochastic Oscillator
- STAA 53.85
- ARQT 82.57
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.